A COMPARATIVE CLINICAL STUDY OF YAVAGRAJADI CHURNA PRATISARANA AND YAVAGRAJADI KAVAL WITH TRIPHALA GUGGULU IN THE MANAGEMENT OF TUNDIKERI (TONSILLITIS)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- improvement in swelling, pain, difficulty in swallowing
研究概览
简要总结
This is a randomized,parallel group trial in department of Shalakyatantra opd at GovernmentAkhandanand Ayurvedic College and Hospital
Ahmedabad,Gujarat. Acharya sushrut mentioned thatTundikeri (Tonsillitis) should be treated with the drugs having propertieslike lekhana, shothahar,sandhaniya, ropan, raktastambhana andvedanasthapana etc. The drug Yavagrajadi yoga and Triphala guggulu have allabove properties.
Therefore in thepresent study Yavagrajadi churna Pratisarana (Local application) andTriphala guggulu (oral medicine) have been selected for clinical trialsin group P. Yavagrajadi kaval(Gargling) and Triphalaguggulu have been selected for clinical trials in group K.
Methods–
In group P, yavagrajadichurna will be applied locally (pratisarana) on tonsils for 2minutes for maximum 3 weeks and patientwill be given orally Triphala guggulu for maximum 5 weeks.
In group K, patientwill be asked to withhold sufficient quantity of yavagrajadi kalka in theoral cavity and will be advised to move the liquid comfortably (kaval) formaximum 3 weeks and patient will be given orally Triphala guggulu formaximum 5 weeks.
In both groupstriphala guggulu will be administered orally with lukewarm water.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 10.00 Year(s) 至 30.00 Year(s)（—）
- 性别
- All
入选标准
- •1 Catarrhal Tonsillitis 2 Follicular Tonsillitis 3 Parenchymatous tonsillitis.
排除标准
- •1 Membranous tonsillitis, 2 Patient with complication of tonsillitis like Peritonsillar Abscess and parapharyngeal Abscess etc 3 Malignancy syphilis or TB presenting as tonsillar disease diabetes Mellitus and Hypertension pregnancy 4 Presence of other somatic or mental disorder requiring treatment 5 Immune compromised patients 6 Patients not willing to be registered for the trial.
结局指标
主要结局
improvement in swelling, pain, difficulty in swallowing
时间窗: 5 weeks
次要结局
未报告次要终点